Corcept Therapeutics Incorporated
CORTCorcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.
Drugs in Pipeline
14
Phase 3 Programs
5
Upcoming Catalysts
3
Next Catalyst
Jul 30, 2026
16dMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
Mifepristone
Depressive Disorder, Major
Relacorilant 150 mg once daily (QD)
Ovarian Cancer
Nab-paclitaxel 100 mg/m^2
Ovarian Neoplasm
Relacorilant
Recurrent Ovarian Cancer
mifepristone 600 mg
Major Depressive Disorder
Miricorlilant
Antipsychotic-induced Weight Gain (AIWG)
Dazucorilant 300 mg
Amyotrophic Lateral Sclerosis
Relacorilant with nab-paclitaxel
Solid Tumors
Nenocorilant 200 mg
Neoplasms
Gemcitabine 1000 mg/m^2
Adenocarcinoma
CORT125281
Metastatic Castration-Resistant Prostate Cancer
Miricorilant
Antipsychotic-induced Weight Gain (AIWG)
CORT125134
Cushing's Syndrome
Miricorilant (Cohort A)
Nonalcoholic Steatohepatitis (NASH)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Mifepristone | Phase 3 | Depressive Disorder, Major | - | - |
Relacorilant 150 mg once daily (QD) | Phase 3 | Ovarian Cancer | - | - |
Nab-paclitaxel 100 mg/m^2 | Phase 3 | Ovarian Neoplasm | - | - |
Relacorilant | Phase 3 | Recurrent Ovarian Cancer | - | - |
mifepristone 600 mg | Phase 3 | Major Depressive Disorder | - | - |
Miricorlilant | Phase 2 | Antipsychotic-induced Weight Gain (AIWG) | - | - |
Dazucorilant 300 mg | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
Relacorilant with nab-paclitaxel | Phase 2 | Solid Tumors | - | - |
Nenocorilant 200 mg | Phase 2 | Neoplasms | - | - |
Gemcitabine 1000 mg/m^2 | Phase 2 | Adenocarcinoma | - | - |
CORT125281 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | - | - |
Miricorilant | Phase 2 | Antipsychotic-induced Weight Gain (AIWG) | - | - |
CORT125134 | Phase 2 | Cushing's Syndrome | - | - |
Miricorilant (Cohort A) | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Corcept Therapeutics Incorporated's drug pipeline?→
CatalystAlert tracks 14 drug candidates in Corcept Therapeutics Incorporated's (CORT) pipeline across Phase 3, Phase 2. Its lead program is Mifepristone (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Corcept Therapeutics Incorporated's next FDA catalyst?→
Corcept Therapeutics Incorporated's (CORT) next tracked catalyst is a Earnings expected July 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CORT biotech catalysts?→
Add CORT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Corcept Therapeutics Incorporated's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.